Lyra Therapeutics, Inc.
LYRA
$10.68
$0.403.89%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -12.44% | 7.18% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -12.44% | 7.18% | |||
| Cost of Revenue | -23.36% | 7.79% | |||
| Gross Profit | 23.73% | -7.81% | |||
| SG&A Expenses | -9.69% | -8.09% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -18.41% | 1.44% | |||
| Operating Income | 18.53% | -1.33% | |||
| Income Before Tax | 22.15% | 7.53% | |||
| Income Tax Expenses | -33.33% | -14.29% | |||
| Earnings from Continuing Operations | 22.15% | 7.53% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 22.15% | 7.53% | |||
| EBIT | 18.53% | -1.33% | |||
| EBITDA | 18.59% | -0.17% | |||
| EPS Basic | 22.43% | 7.61% | |||
| Normalized Basic EPS | 18.20% | -2.89% | |||
| EPS Diluted | 22.43% | 7.61% | |||
| Normalized Diluted EPS | 18.20% | -2.89% | |||
| Average Basic Shares Outstanding | 0.38% | 0.08% | |||
| Average Diluted Shares Outstanding | 0.38% | 0.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||